These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9814943)

  • 61. G8 support for vaccine initiative draws mixed reactions. HIV-vaccine enterprise promises to mobilise billions of dollars for research and make projects more global.
    Walgate R
    Lancet; 2004 Jun; 363(9426):2055. PubMed ID: 15209077
    [No Abstract]   [Full Text] [Related]  

  • 62. AIDS vaccines: the ethical and societal issues.
    Mirken B
    BETA; 2001; 14(2):41-5. PubMed ID: 11785484
    [No Abstract]   [Full Text] [Related]  

  • 63. 2009--a banner year in AIDS vaccine research and development.
    Kresge KJ
    IAVI Rep; 2009; 13(6):2. PubMed ID: 20210215
    [No Abstract]   [Full Text] [Related]  

  • 64. Efficacy trials for HIV/AIDS vaccines.
    Petricciani JC; Koff WC; Ada GL
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1527-9. PubMed ID: 1466997
    [No Abstract]   [Full Text] [Related]  

  • 65. Guest editorial--preventive vaccines.
    J Biopharm Stat; 2006; 16(4):399-402. PubMed ID: 16892902
    [No Abstract]   [Full Text] [Related]  

  • 66. Canada launches new HIV vaccine development program.
    IAVI Rep; 2007; 11(1):19. PubMed ID: 20213874
    [No Abstract]   [Full Text] [Related]  

  • 67. The enterprise changes course.
    McEnery R
    IAVI Rep; 2011; 15(5):9-13. PubMed ID: 22121546
    [No Abstract]   [Full Text] [Related]  

  • 68. Novel vaccines and adjuvants.
    Buonaguro L
    Curr HIV Res; 2010 Jun; 8(4):273. PubMed ID: 20462398
    [No Abstract]   [Full Text] [Related]  

  • 69. AIDS vaccines: the ethical and social issues.
    Mirken B
    BETA; 2001; 14(2):41-5. PubMed ID: 11702766
    [No Abstract]   [Full Text] [Related]  

  • 70. Vaccine reactions.
    Yamazaki S
    Nat Med; 1998 Jul; 4(7):746. PubMed ID: 9662344
    [No Abstract]   [Full Text] [Related]  

  • 71. Local pain, global prescriptions? Using scale to analyse the globalisation of the HIV/AIDS response.
    Campbell C; Cornish F; Skovdal M
    Health Place; 2012 May; 18(3):447-52. PubMed ID: 22469528
    [No Abstract]   [Full Text] [Related]  

  • 72. HIV vaccines: the search for the magic bullet.
    van der Linde I
    S Afr Med J; 1999 Aug; 89(8):825, 828-9. PubMed ID: 10488353
    [No Abstract]   [Full Text] [Related]  

  • 73. Barriers to participation in actual HIV vaccine trials.
    Dhalla S; Poole G
    Curr HIV Res; 2013 Apr; 11(3):238-45. PubMed ID: 23721228
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [A vaccine against HIV--status after ten years of research].
    Schønning K; Hansen JE
    Ugeskr Laeger; 1996 Dec; 158(49):7047-50. PubMed ID: 8999609
    [No Abstract]   [Full Text] [Related]  

  • 75. Canada will have a national HIV vaccine plan.
    Garmaise D
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):29. PubMed ID: 14719491
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The search for an HIV vaccine.
    Makgoba MW; Solomon N; Tucker TJ
    BMJ; 2002 Jan; 324(7331):211-3. PubMed ID: 11809644
    [No Abstract]   [Full Text] [Related]  

  • 77. A transformed global enterprise for an HIV vaccine.
    Tatoud R; Snow W; Esparza J
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25822. PubMed ID: 34806318
    [No Abstract]   [Full Text] [Related]  

  • 78. Vaccine reactions.
    Francis DP; Nowinski RC
    Nat Med; 1998 Jul; 4(7):746. PubMed ID: 9662345
    [No Abstract]   [Full Text] [Related]  

  • 79. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.
    Global HIV/AIDS Vaccine Enterprise
    PLoS Med; 2005 Feb; 2(2):e25. PubMed ID: 15740411
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Designing an AIDS vaccine.
    Laurence J
    AIDS Patient Care STDS; 2001 Sep; 15(9):449-51. PubMed ID: 11587629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.